The future of antihypertensive treatment: From myth to imminent reality

Hellenic Journal of Cardiology

Volumn 49, Issue 5, 2008, Pages 377-378

  Stefanadis, Christodoulos I ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; AMINOETHYL BENZENESULFONOFLUORIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APOCYNIN; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENYLIODONIUM SALT; GUANYLATE CYCLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN KINASE C INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN INHIBITOR; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VAS 2870;

ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GENE THERAPY; GENETIC POLYMORPHISM; GENOTYPE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMMUNOTHERAPY; MONOTHERAPY; NONHUMAN; PATHOGENESIS; THROMBOCYTE AGGREGATION; UNSPECIFIED SIDE EFFECT; VACCINATION; VASODILATATION;

EID: 57349177527     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. Lawes CM, Vander Hoorn S, Rodgers A; for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008; 371: 1513-1518.
2. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006; 368: 1449-1456.
3. Masuyama H, Tsuruda T, Kato J, et al. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension. 2006; 48: 972-978.
4. Zieman SJ, Melenovsky V, Clattenburg L, et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens. 2007; 25: 577-583.
5. Tsioufis C, Dimitriadis K, Selima M, et al. Low-grade inflammation and hypoadiponectinemia have an additive detrimental effect on aortic stiffness in essential hypertensive patients. Eur Heart J. 2007; 28: 1162-1169.
6. Karagiannis A, Athyros VG, Papageorgiou A, Tziomalos K, Elisaf M. Should atenolol still be recommended as first-line therapy for primary hypertension? Hellenic J Cardiol. 2006; 47: 298-307.
7. Williams HC, Griendling KK. NADPH oxidase inhibitors: new antihypertensive agents? J Cardiovasc Pharmacol. 2007; 50: 9-16.
8. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure? A meta-analysis of randomised, controlled trials. Hypertension. 2007; 49: 792-798.
9. Kumai T, Tateishi T, Tanaka M, Watanabe M, Shimizu H, Kobayashi S. Tyrosine hydroxylase antisense gene therapy causes hypotensive effects in the spontaneously hypertensive rats. J Hypertens. 2001; 19: 1769-1773.
10. Pachori AS, Numan MT, Ferrario CM, Diz DM, Raizada MK, Katovich MJ. Blood pressure independent attenuation of cardiac hypertrophy by AT1R-AS gene therapy. Hypertension. 2002; 39: 969-975.
11. Kurland L, Liljedahl U, Karlsson J, et al. Angiotensinogen gene polymorphisms: relationships to blood pressure response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens. 2004; 17: 8-13.
12. Tissot AC, Maurer P, Nussberger J, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomized, placebo-controlled phase IIa study. Lancet. 2008; 371: 821-828.